Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018

JAMA. 2019 Apr 23;321(16):1627-1629. doi: 10.1001/jama.2019.2990.

Abstract

This study uses Medicaid drug utilization data to describe reimbursement and market share of long-acting insulins before and after approval of new insulin products and to estimate savings associated with a “biosimilar” for insulin glargine approved in 2015.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Biosimilar Pharmaceuticals / economics*
  • Biosimilar Pharmaceuticals / therapeutic use
  • Cost Savings
  • Drug Costs / trends
  • Drug Utilization / economics
  • Drug Utilization / trends*
  • Humans
  • Insulin Glargine / therapeutic use
  • Insulin, Long-Acting / economics*
  • Insulin, Long-Acting / therapeutic use
  • Insurance, Health, Reimbursement / trends*
  • Medicaid / economics
  • Medicaid / trends*
  • United States

Substances

  • Biosimilar Pharmaceuticals
  • Insulin, Long-Acting
  • Insulin Glargine